Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8

Explore clinical trials studying Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8. Study availability and eligibility vary by location and protocol.

13 public trials 3 recruiting studies

Refine in advanced search Browse all conditions

Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 trial results

Active, Not Recruiting

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

NCT03776487

Conditions: Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, +25 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

NCT04220827

Conditions: Abdominal Neoplasms, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, +21 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

NCT04522336

Conditions: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, +16 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8

Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 trial results

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Related conditions